Journal article

Patient-derived xenograft (PDX) models in basic and translational breast cancer research

Lacey E Dobrolecki, Susie D Airhart, Denis G Alferez, Samuel Aparicio, Fariba Behbod, Mohamed Bentires-Alj, Cathrin Brisken, Carol J Bult, Shirong Cai, Robert B Clarke, Heidi Dowst, Matthew J Ellis, Eva Gonzalez-Suarez, Richard D Iggo, Peter Kabos, Shunqiang Li, Geoffrey J Lindeman, Elisabetta Marangoni, Aaron McCoy, Funda Meric-Bernstam Show all

Cancer and Metastasis Reviews | SPRINGER | Published : 2016

Grants

Awarded by Innovative Medicines Initiative Joint Undertaking for the PREDECT consortium


Awarded by JAX Cancer Center


Awarded by ISCIII


Awarded by INCa-DGOS-INSERM SIRIC BRIO grant


Awarded by NIH, Grohne Cancer Research Fund


Awarded by BCM Cancer Center


Awarded by BCM Breast Cancer SPORE


Awarded by NIH/NCI


Awarded by CTSA


Awarded by Australian National Health and Medical Research Council (NHMRC)


Awarded by NHMRC Research Fellowship


Awarded by NHMRC Australia Fellowship


Awarded by Cancer Prevention and Research Institute of Texas (CPRIT)


Awarded by Cancer Center Support grant of the National Institutes of Health/National Cancer Institute


Awarded by NIH


Awarded by DOD Breast Cancer Research Program


Awarded by Komen for the Cure Promise grant



Funding Acknowledgements

Samuel Aparicio-Supported by the BC Cancer Foundation, Canadian Breast Cancer Foundation, CIHR, Canadian Foundation for Innovation, Stand Up to Cancer Canada, Canadian Cancer Research Institute, and Terry Fox Research InstituteFariba Behbod-Supported by R01-NIH/NCI-R01CA172764, NIH/NCI-R21CA187890, AACR-Breast Cancer Research Foundation-2014 Translational Breast Cancer Research, and NIH/NCI-R21CA185460Cathrin Brisken-The research leading to these results has received support from the Swiss Cancer League, the SNF, and the Innovative Medicines Initiative Joint Undertaking (grant agreement no. 115188) for the PREDECT consortium (www.predect.eu) resources composed of financial contribution from EU-FP7 and EFPIA companies in kind contribution. The Web address of the Innovative Medicines Initiative is http://www.imi.europa.eu/.Carol J. Bult-This work was supported in part by the Maine Cancer Foundation, The Jackson Laboratory Director's Innovation Fund, and JAX Cancer Center grant P30 CA034196.Robert Clarke and Denis Alferez-This work was funded by Cancer Research UK and Breast Cancer Now. We would like to thank all patients who donated tissue to this study and the Manchester Cancer Research Centre Biobank for consenting patients and collecting tissue.Eva Gonzalez-Suarez-This work was supported in part by grants to Eva Gonzalez Suarez by the Spanish Ministry of Economy and Competitivity MINECO and from the ISCIII (SAF2008-01975, SAF2011-22893, SAF2014-55997), PIE13/00022, co-funded by FEDER funds/European Regional Development Fund (ERDF-a way to build Europe), by a Career Catalyst grant from the Susan Komen Foundation and by institutional funds provided by the Generalitat de Catalunya.Richard Iggo-This work was supported by the "Fondation pour la lutte contre le cancer et pour des recherches medico-biologiques," the INCa-DGOS-INSERM 6046 SIRIC BRIO grant, and the French Cancer League (Comite de la Charente Maritime).Peter Kabos-NIH grant CA164048, Grohne Cancer Research FundMichael T. Lewis-This work was supported in part by the Breast Cancer Research Foundation, the Emma Jacobs Clinical Breast Cancer Fund, the Susan G. Komen Foundation, Cancer Fighters of Houston, BCM Cancer Center grant P30 CA125123, BCM Breast Cancer SPORE P50 CA50183, NIH/NCI grant R01 CA112305, and NIH/NCI grant U54 CA149196. The authors also acknowledge the joint participation by Diana Henry Helis Medical Research Foundation through its direct engagement in the continuous active conduct of medical research in conjunction with Baylor College of Medicine and its "Blood-borne BioMarkers for Detection of Breast Cancer" Program.Shunqiang Li-Susan G. Komen for the Cure (BCTR0707808, KG090422, and PG12220321), Breast Cancer Research Foundation, CTSA grant UL1 RR024992, and The Fashion Footwear Charitable Foundation, Inc.Geoffrey J. Lindeman and Jane E. Visvader-Received funding support from the Australian National Health and Medical Research Council (NHMRC; 1016701, 1040978, 1086727, 1085191); NHMRC Independent Research Institute Infrastructure Support Scheme (IRIISS) (to WEHI); the Victorian State Government through the Victorian Cancer Agency and Operational Infrastructure Support; the National Breast Cancer Foundation (Australia); the Cancer Therapeutics CRC; and the Australian Cancer Research Foundation. G.J.L. is supported by an NHMRC Research Fellowship (1078730); J.E.V. is supported by an NHMRC Australia Fellowship (1037230).Helen Piwnica-Worms-This work was supported in part by the Cazalot Breast Cancer Model Resource, The Susan G. Komen Foundation, and The Cancer Prevention and Research Institute of Texas (CPRIT) RP150148.Jorge Reis-Filho-Research reported in this publication was supported in part by a grant from the Breast Cancer Research Foundation and a Cancer Center Support grant of the National Institutes of Health/National Cancer Institute (grant no. P30CA008748). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Carol Sartorius-NIH grant CA140985.Alana Welm-The Noreen Fraser Foundation, METAvivor Foundation, AACR Susan G. Komen Career Catalyst award, DOD Breast Cancer Research Program grants W81XWH-08-1-0109 and BC112623, and NIH/NCI grants 1R01CA166422 and 1R01CA173903Max Wicha-R35: CA129765; RO1 CA101860, Komen for the Cure Promise grant, and Breast Cancer Research Foundation grant